Mode
Text Size
Log in / Sign up
N/A Completed N=567

Varenicline Observational Investigation In The Cessation of Smoking

Source: ClinicalTrials.gov NCT00669240 ↗
Enrolled (actual)
567
Serious AEs
1.3%
Results posted
Jul 2010
Primary outcomePrimary: Number of Participants With Non-serious Adverse Events (AEs) or Serious Adverse Events (SAEs) — 131; 7 participants

Summary

The purpose of this study is to determine the safety and efficacy of varenicline in the real-world environment of smokers attending primary care in routine clinical practice with the addition of being offered behavioral support "Life REWARDS"TM. This is a non-interventional study.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Non-serious Adverse Events (AEs) or Serious Adverse Events (SAEs)
131; 7 —
SECONDARY
Number of Participants Whose Smoking Status Was Known at the End of 12 Weeks
356; 135 —
SECONDARY
Number of Participants in Belgium Whose Smoking Status Was Known at the End of 12 Weeks and 24 Weeks
138; 41; 103; 34 —
SECONDARY
Number of Treatment Responders at Week 12
356 —
SECONDARY
Number of Treatment Responders in Belgium at Week 12 and at Week 24
138; 103 —
SECONDARY
Number of Participants With Smoking Cessation Assessments at Weekly Intervals From Week 3 Through Week 11
105; 129; 84; 65; 50; 45 —
SECONDARY
Number of Treatment Responders at Weekly Intervals From Week 3 Through Week 11
65; 89; 62; 50; 43; 35 —
SECONDARY
Number of Participants for Whom a Maintenance Period of Varenicline Was Prescribed at the End of Week 12
60 —
SECONDARY
Number of Participants Who Received Varenicline, by Duration of Treatment in Days
3; 8; 19; 48; 85; 280 —
SECONDARY
Number of Participants Who Registered With LifeREWARDS On-line Behavioral Support Program
65; 0; 3; 2 —
SECONDARY
Minnesota Nicotine Withdrawal Scale (MNWS) Subscale Scores for Participants in Belgium
0.7; 0.6; 0.8; 0.5; 1.1; 0.8 —

Eligibility Criteria

Inclusion Criteria

  • The patients enrolled should be of legal adult age who regularly smoke and of which the main tobacco product is cigarettes.
  • The patients must be willing to make an attempt to stop smoking.

Exclusion Criteria

  • All patients enrolled should meet the usual prescribing criteria for varenicline as per SmPC and should be entered into the trial at the Investigators discretion.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00669240). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search